AQUILA STUDY IN GERMANY - REAL WORLD ADHERENCE AND PERSISTENCE OF SECUKINUMAB TREATMENT IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS PATIENTS - AN INTERIM ANALYSIS

被引：8
|
作者：
Kiltz, Uta [1 ,2 ]
Peterlik, Daniel [3 ]
Winkelmann, Veronika [3 ]
Tony, Hans-Peter [4 ]
机构：
[1] Rheumazentrum Ruhrgebiet, Herne, Germany
[2] Ruhr Univ, Bochum, Germany
[3] Novartis Pharma GmbH, Clin Res Immunol Hepatol & Dermatol, Nurnberg, Germany
[4] Univ Klin, Med Klin 2, Rheumatol Immunol, Wurzburg, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; DOUBLE-BLIND;
D O I：
10.1136/annrheumdis-2019-eular.435
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0705
引用
收藏
页码：1814 / 1815
页数：2
相关论文
共 50 条
  • [31] A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study
    Zagni, Emanuela
    Frassi, Micol
    Mariano, Giuseppa Pagano
    Fusaro, Enrico
    Lomater, Claudia
    Del Medico, Patrizia
    Iannone, Florenzo
    Foti, Rosario
    Limonta, Massimiliano
    Marchesoni, Antonio
    Raffeiner, Bernd
    Viapiana, Ombretta
    Grassi, Walter
    Grembiale, Rosa Daniela
    Guggino, Giuliana
    Mazzone, Antonino
    Tirri, Enrico
    Perricone, Roberto
    Sarzi Puttini, Pier Carlo
    De Vita, Salvatore
    Conti, Fabrizio
    Zullo, Alessandro
    Simoni, Lucia
    Fiocchi, Martina
    Orsenigo, Roberto
    Colombo, Delia
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [32] Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
    Gossec, Laure
    Siebert, Stefan
    Bergmans, Paul
    de Vlam, Kurt
    Gremese, Elisa
    Joven-Ibanez, Beatriz
    Korotaeva, Tatiana, V
    Lavie, Frederic
    Noel, Wim
    Nurmohamed, Michael T.
    Sfikakis, Petros P.
    Sharaf, Mohamed
    Theander, Elke
    Smolen, Josef S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04) : 496 - 506
  • [33] Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
    Hsia, Elizabeth C.
    Schluger, Neil
    Cush, John J.
    Chaisson, Richard E.
    Matteson, Eric L.
    Xu, Stephen
    Beutler, Anna
    Doyle, Mittie K.
    Hsu, Benjamin
    Rahman, Mahboob U.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (07): : 2068 - 2077
  • [34] Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
    Mease, Philip J.
    Ogdie, Alexis
    Tesser, John
    Shiff, Natalie J.
    Zhao, Ruizhi Sophia
    Chakravarty, Soumya D.
    Kelleman, Michael
    Dodge, Rhiannon
    McLean, Robert R.
    Broadwell, Aaron
    Kavanaugh, Arthur
    Merola, Joseph F.
    ACR OPEN RHEUMATOLOGY, 2024, 6 (05) : 304 - 311
  • [35] Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
    Gossec, Laure
    Siebert, Stefan
    Bergmans, Paul
    de Vlam, Kurt
    Gremese, Elisa
    Joven-Ibanez, Beatriz
    Korotaeva, Tatiana, V
    Lavie, Frederic
    Noel, Wim
    Nurmohamed, Michael T.
    Sfikakis, Petros P.
    Theander, Elke
    Smolen, Josef S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 823 - 830
  • [36] Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
    Gottlieb, Alice B.
    Deodhar, Atul
    Mcinnes, Iain B.
    Baraliakos, Xenofon
    Reich, Kristian
    Schreiber, Stefan
    Bao, Weibin
    Marfo, Kwaku
    Richards, Hanno B.
    Pricop, Luminita
    Shete, Abhijit
    Trivedi, Vivek
    Keefe, Deborah
    Papavassilis, Charis C.
    Jagiello, Piotr
    Papanastasiou, Philemon
    Mease, Philip J.
    Lebwohl, Mark
    ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [37] Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis
    Codreanu, Catalin
    Sirova, Klara
    Jarosova, Katerina
    Batalov, Anastas
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (10) : 1763 - 1769
  • [38] Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study
    Napolitano, Maddalena
    Costa, Luisa
    Caso, Francesco
    Megna, Matteo
    Scarpa, Raffaele
    Balato, Nicola
    Ayala, Fabio
    Balato, Anna
    CLINICAL RHEUMATOLOGY, 2017, 36 (07) : 1589 - 1593
  • [39] Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study
    Augustin, M.
    Sator, P. G.
    von Kiedrowski, R.
    Conrad, C.
    Rigopoulos, D.
    Romanelli, M.
    Ghislain, P-D
    Torres, T.
    Ioannides, D.
    Aassi, M.
    Schulz, B.
    Jagiello, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (10) : 1796 - 1804
  • [40] Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
    Mease, Philip J.
    Ogdie, Alexis R.
    Tesser, John
    Shiff, Natalie
    Lin, Iris
    Chakravarty, Soumya
    Kelleman, Mike
    Dodge, Rhiannon
    McLean, Robert
    Broadwell, Aaron
    Kavanaugh, Arthur
    Merola, Joseph F.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2767 - 2770
12345